Thesis Recent clinical trial delays and negative market sentiment towards biotech stocks have contributed to a bearish outlook for CEL-SCI.
★ Analysts see FY2027 revenue reaching $6M — +27.3% growth in a single year.
What Moves the Stock 01 Results from clinical trials for Multikine, particularly Phase III outcomes 02 Regulatory approvals from the FDA or other health authorities 03 Partnership announcements or funding agreements 04 Market sentiment towards biotechnology stocks 05 Product sales from Multikine (0% of total, as it is not yet commercialized) 06 Grants and funding for clinical trials (unknown %) 07 Collaborative agreements with pharmaceutical companies (unknown %) 08 Immunotherapy advancements in oncology 0.7 1.8 2.9 4.0 5.2 1.60 CVM Daily 1.60 Apr '26 May '26 Jul '26 Aug '26
My Notes "Investors are increasingly cautious as uncertainties around trial outcomes loom." Moat: CEL-SCI's proprietary technology offers a unique approach to immunotherapy, but the moat is vulnerable to rapid advancements in the biotech… growth - Investors looking for high-risk, high-reward opportunities in the biotech space. Moderate - Rising interest rates could increase the cost of capital for funding clinical trials… Watch on earnings: Clinical trial enrollment rates for Multikine, Cash burn rate and available liquidity, FDA approval timelines for new therapies. One Sentence Summary: CEL-SCI: the story is balanced — results from clinical trials for multikine, particularly phase iii outcomes.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.